Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical
Infections (all grades) · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab may leads to higher infections (all grades) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
1 finding from 1 review
- RR 1.32 [1.01, 1.74]2 studies · 356 participantsLow